CD137 Regulates NFATc1 Expression in Mouse VSMCs through TRAF6/NF-κB p65 Signaling Pathway

Figure 5

Inhibition of NF-κB significantly attenuated the agonist-CD137mAb induced increasing of NFATc1 in VSMCs. The VSMCs were treated with PDTC (the specific inhibitor of the NF-κB). (a) The cells were treated with 10 nM, 20 nM, and 30 nM PDTC for 30, 60, 90, and 120 min. Total RNA were isolated from the harvested cells. The mRNA levels of NFATc1 were determined by qRT-PCR. (b, c, d, e) The cells were pretreated with 30 nM PDTC for 30 min before agonist-CD137mAb administration. Total RNA and cytoplasm and nucleus protein were isolated from the harvested cells. The cells were harvested for examination of p-p65 cytoplasm (b) and nucleus (c) and protein levels of NFATc1 (e) by Western blot and mRNA levels of NFATc1 (d) by qRT-PCR. ; .

(a)

(b)

(c)

(d)

(e)